ml9b00258_si_001.pdf (622.88 kB)
Discovery of N‑(1-Acryloylazetidin-3-yl)-2-(1H‑indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C
journal contribution
posted on 2019-08-20, 18:58 authored by Youngsook Shin, Joon Won Jeong, Ryan P. Wurz, Pragathi Achanta, Tara Arvedson, Michael D. Bartberger, Iain D. G. Campuzano, Ray Fucini, Stig K. Hansen, John Ingersoll, Jeffrey S. Iwig, J. Russell Lipford, Vu Ma, David J. Kopecky, John McCarter, Tisha San Miguel, Christopher Mohr, Sudi Sabet, Anne Y. Saiki, Andrew Sawayama, Steven Sethofer, Christopher M. Tegley, Laurie P. Volak, Kevin Yang, Brian A. Lanman, Daniel A. Erlanson, Victor J. CeeKRAS
regulates many cellular processes including proliferation,
survival, and differentiation. Point mutants of KRAS have long been
known to be molecular drivers of cancer. KRAS p.G12C, which occurs in approximately 14% of lung adenocarcinomas, 3–5%
of colorectal cancers, and low levels in other solid tumors, represents
an attractive therapeutic target for covalent inhibitors. Herein,
we disclose the discovery of a class of novel, potent, and selective
covalent inhibitors of KRASG12C identified through a custom
library synthesis and screening platform called Chemotype Evolution
and structure-based design. Identification of a hidden surface groove
bordered by H95/Y96/Q99 side chains was key to the optimization of
this class of molecules. Best-in-series exemplars exhibit a rapid
covalent reaction with cysteine 12 of GDP-KRASG12C with
submicromolar inhibition of downstream signaling in a KRASG12C-specific manner.